JP2024531900A5 - - Google Patents
Info
- Publication number
- JP2024531900A5 JP2024531900A5 JP2024505469A JP2024505469A JP2024531900A5 JP 2024531900 A5 JP2024531900 A5 JP 2024531900A5 JP 2024505469 A JP2024505469 A JP 2024505469A JP 2024505469 A JP2024505469 A JP 2024505469A JP 2024531900 A5 JP2024531900 A5 JP 2024531900A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- seq
- cancer
- amino acid
- sequence number
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2021/109041 | 2021-07-28 | ||
| CN2021109041 | 2021-07-28 | ||
| CNPCT/CN2022/104562 | 2022-07-08 | ||
| CN2022104562 | 2022-07-08 | ||
| PCT/US2022/074286 WO2023010100A1 (en) | 2021-07-28 | 2022-07-28 | Novel anti-sirpa antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024531900A JP2024531900A (ja) | 2024-09-03 |
| JP2024531900A5 true JP2024531900A5 (https=) | 2025-08-04 |
Family
ID=85087323
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024505469A Pending JP2024531900A (ja) | 2021-07-28 | 2022-07-28 | 新規の抗ｓｉｒｐａ抗体 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250270315A1 (https=) |
| EP (1) | EP4377358A4 (https=) |
| JP (1) | JP2024531900A (https=) |
| KR (1) | KR20240039006A (https=) |
| CN (1) | CN118076638A (https=) |
| AU (1) | AU2022317822A1 (https=) |
| CA (1) | CA3227854A1 (https=) |
| TW (1) | TW202313699A (https=) |
| WO (1) | WO2023010100A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120569409A (zh) * | 2023-01-18 | 2025-08-29 | 科望(苏州)生物医药科技有限公司 | 靶向sirpa和claudin 18.2的双特异性分子 |
| EP4702053A1 (en) * | 2023-04-27 | 2026-03-04 | LaNova Medicines Limited | Combination treatment targeting sirpa and claudin 18.2 |
| WO2025140296A1 (zh) * | 2023-12-26 | 2025-07-03 | 上海宏成药业有限公司 | 抗dll3抗体或其抗原结合片段及其用途 |
| KR20250164033A (ko) * | 2024-05-14 | 2025-11-24 | 주식회사 지놈앤컴퍼니 | 항-bcam 항체 및 이의 컨쥬게이트 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108290936B (zh) * | 2015-08-14 | 2022-07-12 | 默沙东公司 | 抗tigit抗体 |
| SG11202012338QA (en) * | 2018-07-10 | 2021-01-28 | Univ Kobe Nat Univ Corp | ANTI-SIRPa ANTIBODY |
| AU2020286285A1 (en) * | 2019-08-20 | 2021-03-11 | Elpiscience (Suzhou) Biopharma, Ltd. | Novel anti-SIRPa antibodies |
| KR20220119473A (ko) * | 2019-12-24 | 2022-08-29 | 라노바 메디신즈 리미티드 컴파니 | 항-SIRPα 단클론성 항체 및 그것의 용도 |
-
2022
- 2022-07-28 CA CA3227854A patent/CA3227854A1/en active Pending
- 2022-07-28 AU AU2022317822A patent/AU2022317822A1/en active Pending
- 2022-07-28 JP JP2024505469A patent/JP2024531900A/ja active Pending
- 2022-07-28 KR KR1020247006211A patent/KR20240039006A/ko active Pending
- 2022-07-28 CN CN202280053002.XA patent/CN118076638A/zh active Pending
- 2022-07-28 TW TW111128255A patent/TW202313699A/zh unknown
- 2022-07-28 WO PCT/US2022/074286 patent/WO2023010100A1/en not_active Ceased
- 2022-07-28 US US18/292,922 patent/US20250270315A1/en active Pending
- 2022-07-28 EP EP22850533.5A patent/EP4377358A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024531900A5 (https=) | ||
| JP2021514664A5 (https=) | ||
| AU2017226510C1 (en) | A pdl-1 antibody, pharmaceutical composition thereof and use thereof | |
| JP2024059609A5 (https=) | ||
| JP2022515318A5 (https=) | ||
| JP2021524249A5 (https=) | ||
| JP2020501531A5 (https=) | ||
| WO2014180577A1 (en) | Bispecific constructs and their use in the treatment of various diseases | |
| JP2018526972A5 (https=) | ||
| JP2022535553A5 (https=) | ||
| JP2013502913A5 (https=) | ||
| JP2025500971A5 (https=) | ||
| WO2023060277A1 (en) | Composition of multispecific antibodies targeting cdh17-expressing tumors and method of making and using thereof | |
| JP2024531462A (ja) | Ｆａｐ／ｃｄ４０結合分子及びその医薬的使用 | |
| JP2024538669A5 (https=) | ||
| JP2024504124A5 (https=) | ||
| JP2019513410A5 (https=) | ||
| JP2024534468A5 (https=) | ||
| CN111712521A (zh) | Cd38蛋白抗体及其应用 | |
| JP2024527043A5 (https=) | ||
| JP2023525991A5 (https=) | ||
| JP2025538642A (ja) | Ｃｌｄｎ１８．２／４－１ｂｂ結合タンパク質及びその医薬的使用 | |
| JP2025504496A5 (https=) | ||
| TW202328183A (zh) | 人類介白素-4受體α抗體 | |
| WO2020221791A1 (en) | Combination of her2 antibodies |